Vedanta lands $60M to push C. diff microbiome drug through Phase 3
What's the deal? Vedanta Biosciences has raised $60 million in a late-stage venture round to fund its microbiome therapy for C. difficile infection through a Phase 3 readout. The company is one of the microbiome field's longest-standing biotechs.
What's the endgame? The cash pushes Vedanta toward a Phase 3 readout in C. difficile , a recurring bacterial infection. A positive result would move its candidate closer to market.
Why now? Late-stage trials are costly, and the raise gives Vedanta the runway to reach the readout that will define the program.
The signal: At $60 million, the round sits in roughly the 71st percentile by amount — sizeable, but not a blockbuster. It shows investors are still willing to back the microbiome sector's veterans, even after years of clinical setbacks across the field.
Read more: Endpoints
Image credit: National Institutes of Health (NIH)
